Best Practice & Research Clinical Anaesthesiology
Volume 22, Issue 2 , Pages 243-252 , June 2008

Physiology and pathophysiology of the vasopressinergic system

References 

  1. Oliver G, Schaefer EA. On the physiological action of extract of pituitary body and certain other glandular organs. The Journal of Physiology. 1895;18:277–279
  2. Mutlu GM, Factor P. Role of vasopressin in the management of septic shock. Intensive Care Medicine. 2004;30:1276–1291
  3. Oshikawa S, Tanoue A, Koshimizu TA, et al. Vasopressin stimulates insulin release from islet cells through V1b receptors: a combined pharmacological/knockout approach. Molecular Pharmacology. 2004;65:623–629
  4. Tanoue A, Ito S, Honda K, et al. The vasopressin V1b receptor critically regulates hypothalamic-pituitary-adrenal axis activity under both stress and resting conditions. The Journal of Clinical Investigation. 2004;113:302–309
  5. Weingartner H, Gold P, Ballenger JC, et al. Effects of vasopressin on human memory functions. Science. 1981;211:601–603
  6. Bielsky IF, Hu SB, Ren X, et al. The V1a vasopressin receptor is necessary and sufficient for normal social recognition: a gene replacement study. Neuron. 2005;47:503–513
  7. Acher R, Chauvet J, Chauvet MT. Man and the chimaera. Selective versus neutral oxytocin evolution. Advances in Experimental Medicine and Biology. 1995;395:615–627
  8. de Bree FM, Burbach JP. Structure–function relationships of the vasopressin prohormone domains. Cellular and Molecular Neurobiology. 1998;18:173–191
  9. Sklar AH, Schrier RW. Central nervous system mediators of vasopressin release. Physiological Reviews. 1983;63:1243–1280
  10. Baylis PH. Osmoregulation and control of vasopressin secretion in healthy humans. American Journal of Physiology. 1987;253:R671–R678
  11. Feldberg W, Guertzenstein PG, Rocha e Silva M. Vasopressin release by nicotine: the site of action. British Journal of Pharmacology. 1975;54:463–474
  12. den Ouden DT, Meinders AE. Vasopressin: physiology and clinical use in patients with vasodilatory shock: a review. Netherlands Journal of Medicine. 2005;63:4–13
  13. Kam PC, Williams S, Yoong FF. Vasopressin and terlipressin: pharmacology and its clinical relevance. Anaesthesia. 2004;59:993–1001
  14. Bankir L. Antidiuretic action of vasopressin: quantitative aspects and interaction between V1a and V2 receptor-mediated effects. Cardiovascular Research. 2001;51:372–390
  15. Quillen EW, Cowley AW. Influence of volume changes on osmolality-vasopressin relationships in conscious dogs. American Journal of Physiology. 1983;244:H73–H79
  16. Schrier RW, Berl T, Anderson RJ. Osmotic and nonosmotic control of vasopressin release. American Journal of Physiology. 1979;236:F321–F332
  17. Leng G, Brown CH, Russell JA. Physiological pathways regulating the activity of magnocellular neurosecretory cells. Progress in Neurobiology. 1999;57:625–655
  18. Bahr V, Franzen N, Oelkers W, et al. Effect of exogenous glucocorticoid on osmotically stimulated antidiuretic hormone secretion and on water reabsorption in man. European Journal of Endocrinology. 2006;155:845–848
  19. Birnbaumer M. Vasopressin receptors. Trends in Endocrinology and Metabolism. 2000;11:406–410
  20. Oakley RH, Laporte SA, Holt JA, et al. Association of beta-arrestin with G protein-coupled receptors during clathrin-mediated endocytosis dictates the profile of receptor resensitization. The Journal of Biological Chemistry. 1999;274:32248–32257
  21. Barberis C, Mouillac B, Durroux T. Structural bases of vasopressin/oxytocin receptor function. The Journal of Endocrinology. 1998;156:223–229
  22. Birnbaumer M, Seibold A, Gilbert S, et al. Molecular cloning of the receptor for human antidiuretic hormone. Nature. 1992;357:333–335
  23. Chini B, Manning M. Agonist selectivity in the oxytocin/vasopressin receptor family: new insights and challenges. Biochemical Society Transactions. 2007;35:737–741
  24. Neves SR, Ram PT, Iyengar R. G protein pathways. Science. 2002;296:1636–1639
  25. Holmes CL, Landry DW, Granton JT. Science review: vasopressin and the cardiovascular system part 1 – receptor physiology. Critical Care (London, England). 2003;7:427–434
  26. George CP, Messerli FH, Genest J, et al. Diurnal variation of plasma vasopressin in man. The Journal of Clinical Endocrinology and Metabolism. 1975;41:332–338
  27. Nadal M. Secretory rhythm of vasopressin in healthy subjects with inversed sleep–wake cycle: evidence for the existence of an intrinsic regulation. European Journal of Endocrinology. 1996;134:174–176
  28. Forrest P. Vasopressin and shock. Anaesthesia and Intensive Care. 2001;29:463–472
  29. Williams TD, Da Costa D, Mathias CJ, et al. Pressor effect of arginine vasopressin in progressive autonomic failure. Clinical Science (London). 1986;71:173–178
  30. Peters HP, Robben JH, Deen PM, Wetzels JF. Water in health and disease: new aspects of disturbances in water metabolism. Netherlands Journal of Medicine. 2007;65:325–332
  31. Robertson GL. Abnormalities of thirst regulation. Kidney International. 1984;25:460–469
  32. Bartter FC, Schwartz WB. The syndrome of inappropriate secretion of antidiuretic hormone. American Journal of Medicine. 1967;42:790–806
  33. Multz AS. Vasopressin dysregulation and hyponatremia in hospitalized patients. Journal of Intensive Care Medicine. 2007;22:216–223
  34. Rai A, Whaley-Connell A, McFarlane S, Sowers JR. Hyponatremia, arginine vasopressin dysregulation, and vasopressin receptor antagonism. American Journal of Nephrology. 2006;26:579–589
  35. Soupart A, Gross P, Legros JJ, et al. Successful long-term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with satavaptan (SR121463B), an orally active nonpeptide vasopressin V2-receptor antagonist. Clinical Journal of the American Society of Nephrology. 2006;1:1154–1160
  36. Goldsmith SR. The role of vasopressin in congestive heart failure. Cleveland Clinic Journal of Medicine. 2006;73(Suppl 3):S19–S23
  37. Kalra PR, Anker SD, Coats AJ. Water and sodium regulation in chronic heart failure: the role of natriuretic peptides and vasopressin. Cardiovascular Research. 2001;51:495–509
  38. Chin MH, Goldman L. Correlates of major complications or death in patients admitted to the hospital with congestive heart failure. Archives of Internal Medicine. 1996;156:1814–1820
  39. Klein L, O'Connor CM, Leimberger JD, et al. Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study. Circulation. 2005;111:2454–2460
  40. Kumar S, Rubin S, Mather PJ, Whellan DJ. Hyponatremia and vasopressin antagonism in congestive heart failure. Clinical Cardiology. 2007;30:546–551
  41. Konstam MA, Gheorghiade M, Burnett JC, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. The Journal of the American Medical Association. 2007;297:1319–1331
  42. Gines P, Berl T, Bernardi M, et al. Hyponatremia in cirrhosis: from pathogenesis to treatment. Hepatology. 1998;28:851–864
  43. Morello JP, Salahpour A, Laperriere A, et al. Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants. The Journal of Clinical Investigation. 2000;105:887–895
  44. Holmes CL, Landry DW, Granton JT. Science review: vasopressin and the cardiovascular system part 2 – clinical physiology. Critical Care (London, England). 2004;8:15–23
  45. Landry DW, Levin HR, Gallant EM, et al. Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation. 1997;95:1122–1125
  46. Sharshar T, Blanchard A, Paillard M, et al. Circulating vasopressin levels in septic shock. Critical Care Medicine. 2003;31:1752–1758
  47. Sharshar T, Carlier R, Blanchard A, et al. Depletion of neurohypophyseal content of vasopressin in septic shock. Critical Care Medicine. 2002;30:497–500
  48. Vincent JL. Vasopressin in hypotensive and shock states. Critical Care Clinics. 2006;22:187–197

PII: S1521-6896(08)00028-1

doi: 10.1016/j.bpa.2008.03.004

Best Practice & Research Clinical Anaesthesiology
Volume 22, Issue 2 , Pages 243-252 , June 2008

Article Tools

* Image Usage & Resolution